COGT - Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics | Benzinga
- Plan to initiate global, registration-directed SUMMIT Part 2 study of bezuclastinib in NonAdvSM patients during 1H 2024; present results from complete SUMMIT Part 1 at 2024 AAAAI annual conference in Q1 2024
- On track to complete enrollment in global, pivotal Phase 3 PEAK study of bezuclastinib + sunitinib in 2nd-line GIST patients by end of 2024
- On track to complete enrollment in registration-directed Phase 2 APEX study of bezuclastinib in AdvSM patients by end of 2024
- Plan to initiate Phase 1 trial of CGT4859, a potential best-in-class, potent, selective and reversible FGFR2 inhibitor in 2H 2024
- Company to present at J.P. Morgan 42nd annual healthcare conference today, Tuesday, January 9 at 4:30 p.m. PT / 7:30 p.m. ET
WALTHAM, Mass. and BOULDER, Colo., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company's key 2024 milestones ahead of its presentation at J.P. Morgan's 42nd annual healthcare conference.
"Given the foundation that was established in 2023, we are well positioned to move Cogent forward aggressively this year, including a cash runway expected to carry us into 2026," said Andrew Robbins, President and CEO of Cogent Biosciences. "We strongly believe in bezuclastinib's potential to become the best-in-class cKIT exon 17/18 inhibitor, and in 2024, we plan to complete enrollment in both the PEAK and APEX trials, each of which have the potential, if successful, to support a regulatory approval for bezuclastinib. In addition, we are excited to further describe the differentiation that bezuclastinib offers patients when presenting the results from the complete SUMMIT Part 1 at AAAAI, setting us up to initiate our third bezuclastinib pivotal trial in the first half of the year. Beyond bezuclastinib, the Cogent Research team is creating exceptional molecules, including a growing portfolio of potential best-in-class breast cancer programs."
In 2024, the Company plans to achieve the following milestones:
Bezuclastinib – Systemic Mastocytosis (SM)
- Present data from the complete SUMMIT Part 1 trial in patients with Non-Advanced Systemic Mastocytosis (NonAdvSM) at the 2024 ...